| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
SN40 hydrochloride targets multiple cellular pathways. Its primary target is DNA-PK, with an IC50 of 13 nM. It is also a potent amino acid transport (AAT) inhibitor, with Ki values of 7.29 μM, 2.42 μM, 2.94 μM, 5.55 μM, 24.43 μM, and 5.55 μM for rat ASCT2, human ASCT2, EAAT1, EAAT2, EAAC1, and EAAT5, respectively. Furthermore, it acts as an inhibitor of DNA topoisomerase I.
|
|---|---|
| ln Vitro |
In vitro, SN40 hydrochloride demonstrates potent inhibition of DNA-PK (IC50 = 13 nM). By blocking the NHEJ repair pathway, it significantly enhances ionizing radiation-induced DNA damage and cell death in cells such as MDA-MB-231. It also inhibits amino acid transporters with Kis in the micromolar range. Its effectiveness is being evaluated in various preclinical studies focusing on its therapeutic potential in oncology.
|
| ln Vivo |
In vivo, SN40 hydrochloride is a promising candidate for cancer therapies, particularly for treating solid tumors. By inducing DNA damage and inhibiting DNA repair, the compound may enhance the efficacy of radiation therapy. Its effectiveness is being evaluated in various preclinical studies. However, comprehensive in vivo efficacy data are still under investigation.
|
| Enzyme Assay |
Non-cellular enzyme assays for SN40 hydrochloride involve measuring DNA topoisomerase I activity. The enzyme is incubated with a DNA substrate and varying concentrations of the test compound. DNA-PK inhibition assays are performed using purified DNA-PK enzyme. Additionally, amino acid transport inhibition can be assessed using membrane preparations or purified transporters to determine Ki values.
|
| Cell Assay |
In vitro cellular experiments with SN40 hydrochloride are conducted in cancer cell lines such as MDA-MB-231. Cells are treated with the compound, often in combination with ionizing radiation. DNA damage is assessed using markers such as γ-H2AX foci formation, and cell survival is measured using clonogenic or MTT assays. The compound's ability to radiosensitize cells is quantified by comparing survival fractions.
|
| Animal Protocol |
In vivo animal studies for SN40 hydrochloride are performed in murine xenograft models using human cancer cell lines. Tumor-bearing mice are treated with the compound, typically via oral or intraperitoneal administration, alone or in combination with radiation. Tumor growth is monitored over time, and endpoints include tumor volume measurements, tumor growth delay, and survival analysis.
|
| ADME/Pharmacokinetics |
SN40 hydrochloride has a molecular formula of C18H21ClN2O2 and a molecular weight of 332.82. The CAS number is 2768663-15-4. Purity is typically ≥98%. The compound is soluble in DMSO (~100 mg/mL). It is stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years. It is typically shipped at room temperature.
|
| Toxicity/Toxicokinetics |
Standard toxicity assessments for SN40 hydrochloride are generated during preclinical development. As a DNA-PK and topoisomerase I inhibitor, potential toxicities may include effects on rapidly dividing normal tissues. Comprehensive toxicology studies would assess safety margins and identify target organ toxicities. Researchers should consult the safety data sheet and handle the compound with appropriate laboratory safety precautions.
|
| References | |
| Additional Infomation |
SN40 hydrochloride is also known as (2S,4S)-4-(([1,1'-Biphenyl]-4-ylmethyl)amino)pyrrolidine-2-carboxylic acid hydrochloride. Key references include a patent (WO2022087630 A1). The compound is for research use only and is not for human therapeutic applications.
|
| Exact Mass |
332.129
|
|---|---|
| CAS # |
2768663-15-4
|
| PubChem CID |
169494471
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
360
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1[C@@H](CN[C@@H]1C(=O)O)NCC2=CC=C(C=C2)C3=CC=CC=C3.Cl
|
| InChi Key |
SCVJDDMQQPCHCV-QJHJCNPRSA-N
|
| InChi Code |
InChI=1S/C18H20N2O2.ClH/c21-18(22)17-10-16(12-20-17)19-11-13-6-8-15(9-7-13)14-4-2-1-3-5-14;/h1-9,16-17,19-20H,10-12H2,(H,21,22);1H/t16-,17-;/m0./s1
|
| Chemical Name |
(2S,4S)-4-[(4-phenylphenyl)methylamino]pyrrolidine-2-carboxylic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~300.46 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.51 mM) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 400 μL PEG300 and mix well. Then add 50 μL Tween-80 to the above system and mix well. Then continue to add 450 μL of physiological saline to make up to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.51 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one),clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL of 20% SBE-β-CD saline solution and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 2.5 mg/mL (7.51 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one),clear solution; with ultrasonication. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
